Long-term protective effects of hepatitis A vaccines. A systematic review

Vaccine

Volumn 31, Issue 1, 2012, Pages 3-11

  Ott, Jördis Jennifer ^a   Irving, Greg ^a   Wiersma, Steven Todd ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Duration of protection; Hepatitis A vaccines; Systematic review

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE;

ANTIBODY TITER; ATTENUATION; DRUG EFFICACY; FOLLOW UP; HEPATITIS A; HUMAN; IMMUNOGENICITY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; VACCINATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 84870508850     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.104     Document Type: Review

References (38)

1. Rein D. Modeling the global burden of hepatitis A virus infections in 1990 and 2005. Poster presentation at the Liver Meeting, 2011 , [accessed 02.03.12]. http://liverlearning.aasld.org/aasld/2011/thelivermeeting/14085/doctor.david.rein.modeling.the.global.burden.of.hepatitis.a.virus.infections.html.
2. WHO Hepatitis A vaccines: WHO position paper. Weekly Epidemiological Record 2000, 75:38-44.
3. Purcell R., Emerson S. Natural history and experimental models. Viral Hepatitis 2005, Blackwell Publishing, Oxford. 3rd ed. H. Thomas, S. Lemon, A. Zuckerman (Eds.).
4. Jacobsen K.H., Wiersma S.T. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010, 28:6653-6657.
5. Irving G.J., Yang R., Holden J., Pope D. Hepatitis A immunisation in persons not previously exposed to hepatitis A. Cochrane Database of Systematic Reviews 2011, (3). Art. No. CD009051. 10 1002/14651858.CD0090.
6. Innis B.L., Snitbhan R., Kunasol P., Laorakpongse T., Poopatanakool W., Kozik C.A., et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994, 271:1328-1334.
7. Werzberger A., Mensch B., Kuter B., Brown L., Lewis J., Sitrin R., et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. New England Journal of Medicine 1992, 327:453-457.
8. Van Herck K., Beutels P., Van Damme P., Beutels M., Van den Dries J., Briantais P., Vidor E. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. Journal of Medical Virology 2000, 60:1-7.
9. Van Herck K., Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. Journal of Medical Virology 2001, 63:1-7.
10. Van Herck K., Van Damme P., Lievens M., Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. Journal of Medical Virology 2004, 72:194-196.
11. Wiedermann G., Kundi M., Ambrosch F., Safary A., D'Hondt E., Delem A. Inactivated hepatitis A vaccine: long-term antibody persistence. Vaccine 1997, 15:612-615.
12. Wiens B.L., Bohidar N.R., Pigeon J.G., Egan J., Hurni W., Brown L., Kuter B.J., Nalin D.R. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. Journal of Medical Virology 1996, 49:235-241.
13. Bovier P.A., Bock J., Ebengo T.F., Grösner G., Glaus J., Herzog C., Loutan L. Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine. Journal of Medical Virology 2010, 82:1629-1634.
14. Van Damme P., Banatvala J., Fay O., Iwarson S., McMahon B., Van Herck K., Shouval D., Bonanni P., Connor B., Cooksley G., Leroux-Roels G., Von Sonnenburg F. International consensus group on hepatitis A virus immunity. Hepatitis A booster vaccination: is there a need?. Lancet 2003, 362:1065-1071.
15. Iwarson S., Lindh M., Widerstrom L. Excellent booster response 4-6 y after a single primary dose of an inactivated hepatitis A vaccine. Scandinavian Journal of Infectious Diseases 2002, 34:110-111.
16. Landry P., Tremblay S., Darioli R., Genton B. Inactivated hepatitis A vaccine booster given ≥24 months after the primary dose. Vaccine 2000, 19:399-402.
17. Cederna J.B., Klinzman D., Stapleton J.T. Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine. Vaccine 2000, 18:892-898.
18. Wang X., Ma J., Zhang Y. Immunogenicity and long-term persistence of anti-HAV in groups with different attenuated and inactived hepatitis A vaccine dosage. Zhonghua Liu Xing Bing Xue Za Zhi 2001, 22:111-113. [Article in Chinese].
19. Chan C.Y., Lee S.D., Yu M.I., Wang Y.J., Chang F.Y., Lo K.J. Long-term follow-up of hepatitis A vaccination in children. Vaccine 1999, 17:369-372.
20. Fan P.C., Chang M.H., Lee P.I., Safary A., Lee C.Y. Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years. Vaccine 1998, 16:232-235.
21. Maiwald H., Jilg W., Bock H.L., Löscher T., Sonnenburg F. Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine. Vaccine 1997, 15:346-348.
22. Totos G., Gizaris V., Papaevangelou G. Hepatitis A vaccine: persistence of antibodies 5 years after the first vaccination. Vaccine 1997, 15:1252-1253.
23. Lopez E.L., Contrini M.M., Mistchenko A., Debbag R. Long-term immunity after two doses of inactivated hepatitis A vaccine, in Argentinean children. Pediatric Infectious Disease Journal 2010, 29:568-570.
24. Byrd K.K., Bruden D.L., Bruce M.G., Bulkow L.R., Zanis C.L., Snowball M.M., Homan C.E., Hennessy T.W., Williams J.L., Dunaway E., Chaves S.S., McMahon B.J. Long-term immunogenicity of inactivated hepatitis A vaccine: Follow-up at 15 years. Pediatric Infectious Disease Journal 2010, 5:321-326.
25. Bovier P.A., Farinelli T., Loutan L. Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine. Vaccine 2005, 23:2424-2429.
26. Crum-Cianflone N.F., Wilkins K., Lee A.W., Grosso A., Landrum M.L., Weintrob A., et al. Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. Journal of Infectious Diseases 2011, 203:1815-1823.
27. Bian G.L., Ma R., Dong H.J., Ni H.X., Hu F.J., Chen Y.R., Chen J.Q., Zhou S.Y., Lin Y.X., Xu G.Z. Long-term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children. Vaccine 2010, 28:4798-4801.
28. Zhuang F.C., Qian W., Mao Z.A., Gong Y.P., Jiang Q., Jiang L.M., Chen N.L., Chai S.A., Mao J.S. Persistent efficacy of live attenuated hepatitis A vaccine (H2-strain) after a mass vaccination program. Chinese Medical Journal 2005, 118:1851-1856.
29. Zhuang F.C., Mao Z.A., Jiang L.M., Wu J., Chen Y.Q., Jiang Q., Chen N.L., Chai S.A., Mao J.S. Long-term immunogencity and effectiveness of live attenuated hepatitis A vaccine (H2-strain) - a study on the result of 15 years' follow up. Zhonghua Liu Xing Bing Xue Za Zhi 2010, 31:1332-1335.
30. Liu H.F., Zhang X.J., Zhang J.L., Hao Z.Y., Zhang Z.Y., Ma J.C., Chen J.C., Chu J., Wang X.Y., Xu Z.Y. The immunological effects of three doses of a live attenuated hepatitis A vaccine (H2 strain) in 8 years. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2009, 23:180-181.
31. Wang X.Y., Xu Z.Y., Ma J.C., von Seidlein L., Zhang Y., Hao Z.Y., Han O.P., Zhang Y.L., Tian M.Y., Ouyang P.Y., Zhang Z.Y., Han C.Q., Xing Z.C., Chen J.C. Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: results from 8-year follow-up. Vaccine 2007, 25:446-449.
32. Liu H.F., Zhang X.J., Zhang J.L. Comparison of antibody persistence between live attenuated and inactivated hepatitis A vaccines. Zhongguo Yi Miao He Mian Yi 2009, 15:300-303.
33. Kernéis S., Desaint C., Brichler S., Rey D., Belarbi L., Gordien E., et al. Long-term persistence of humoral immunity after hepatitis A vaccination in HIV-infected adults. Journal of Acquired Immune Deficiency Syndromes 2011, 57:e63-e65.
34. Smith R. Publishing research from developing countries. Statistics in Medicine 2002, 21:2869-2877.
35. Purcell R.H., D'Hondt E., Bradbury R., Emerson S.U., Govindarajan S., Binn L. Inactivated hepatitis A vaccine: active and passive immuno-prophylaxis in chimpanzees. Vaccine 1992, 10:S148-S151.
36. Lemon S.M., Binn L.N. Serum neutralizing antibody response to hepatitis A virus. Journal of Infectious Diseases 1983, 148:1033-1039.
37. Ellis A., Rüttimann R.W., Jacobs R.J., Meyerhoff A.S., Innis B.L. Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted. Revista Panamericana de Salud Publica 2007, 21:345-356.
38. Armstrong G.L., Billah K., Rein D.B., Hicks K.A., Wirth K.E., Bell B.P. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity. Pediatrics 2007, 119:e22-e29.